Back to Search
ROGERIO LILENBAUM, M.D.
M.D.
Medical Oncology Physician
NPI: 1669460366Individual
Specialties, Licenses & Credentials
Specialist
Specialist
Code: 174400000X
ME71970(FL)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
ME71970(FL)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
ME71970(FL)
Research & Publications (20)
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
PMID 19487960·J Thorac Oncol·2009
8-other
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer.
PMID 18449004·J Thorac Oncol·2008
3-trial
New horizons in chemotherapy: platforms for combinations in first-line advanced non-small cell lung cancer.
PMID 18520305·J Thorac Oncol·2008
6-review
Prevalence of poor performance status in lung cancer patients: implications for research.
PMID 18303431·J Thorac Oncol·2008
4-observational
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
PMID 18281658·J Clin Oncol·2008
3-trial
New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2.
PMID 19073514·Clin Lung Cancer·2008
6-review
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
PMID 18388845·Med Care·2008
8-other
Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.
PMID 17951232·J Natl Cancer Inst Monogr·2007
6-review
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).
PMID 17873174·Chest·2007
6-review
A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.
PMID 17409802·J Thorac Oncol·2007
3-trial
Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.
PMID 17545843·J Thorac Oncol·2007
2-rct
Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status.
PMID 17026814·Clin Lung Cancer·2006
8-other
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
PMID 17050867·J Clin Oncol·2006
3-trial
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
PMID 16857812·Clin Cancer Res·2006
7-preclinical
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
PMID 16507327·Lung Cancer·2006
3-trial
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
PMID 17167137·N Engl J Med·2006
3-trial
The evolving role of cetuximab in non-small cell lung cancer.
PMID 16857823·Clin Cancer Res·2006
6-review
New developments in chemotherapy for advanced non-small cell lung cancer.
PMID 16462185·Curr Opin Oncol·2006
6-review
Primary hepatic neuroendocrine carcinoma: an underdiagnosed entity.
PMID 16414542·Ann Diagn Pathol·2006
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 20 YORK ST
NEW HAVEN, CT 06510 - Phone
- (203) 200-2094
Quick Facts
- NPI
- 1669460366
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile